481981

Nifedipine

Relatively selective blocker of L-type Ca²⁺ channels.

• 同義詞: Nifedipine, L-Type Calcium Channel Blocker III
• 經驗公式（希爾表示法）: C₁₇H₁₈N₂O₆
• CAS號碼: 21829-25-4
• 分子量：: 346.33
• MDL號碼: MFCD00057326
• 分類程式碼代碼: 12352200
• NACRES: NA.77

屬性

• 描述: Merck USA index - 14, 6528
• 品質等級: 100
• 化驗: ≥98% (UV)
• 形狀: solid
• 製造商／商標名: Calbiochem^®
• 儲存條件: OK to freeze; protect from light
• 顏色: yellow
• 溶解度: DMSO: soluble; ethanol: soluble
• 運輸包裝: ambient
• 儲存溫度: 10-30°C
• SMILES 字串: [N+](=O)([O-])c1c(cccc1)C2C(=C(NC(=C2C(=O)OC)C)C)C(=O)OC
• InChI: 1S/C17H18N2O6/c1-9-13(16(20)24-3)15(14(10(2)18-9)17(21)25-4)11-7-5-6-8-12(11)19(22)23/h5-8,15,18H,1-4H3
• InChI 密鑰: HYIMSNHJOBLJNT-UHFFFAOYSA-N

描述

一般說明

Relatively selective blocker of L-type Ca²⁺ channels. One of the most extensively studied blockers of 1,4-dihydropyridine-type Ca²⁺ channels, and a pharmacologically-useful vasodilator. Induces apoptosis in human glioblastoma cells.

生化／生理作用

Cell permeable: no

Primary Target
L-type Ca2+ channels

Product does not compete with ATP.

Reversible: no

警告

Toxicity: Harmful & Carcinogenic / Teratogenic (E)

重構

Following reconstitution, refrigerate (-20°C). Stock solutions are stable for up to 3 months at -20°C.

其他說明

Reid, K., et al. 1997. J. Pharmacol. Exp. Ther. 283, 993.
Kondo, S., et al. 1995. J. Neurosurg.82, 469.
Antkiewicz-Michaluk, L., et al. 1994. Eur. J. Pharmacol. 254, 9.
Calabresi, P., et al. 1994. J. Neurosci. 14, 4871.
Akman, M.S., et al. 1993. Endocrinology132, 1286.
Cirillo, M., et al. 1993. Circ. Res.72, 847.
Young, R.J., et al. 1993. Biochim. Biophys. Acta1146, 81.
Janis, R., et al. 1987. Adv. Drug Res.16, 311.

法律資訊

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

安全資訊

• 象形圖: GHS07
• 訊號詞: Warning
• 危險聲明: H302
• 防範說明: P264 - P270 - P301 + P312 - P501
• 危險分類: Acute Tox. 4 Oral
• 儲存類別代碼: 11 - Combustible Solids
• 水污染物質分類（WGK）: WGK 1
• 閃點（°F）: Not applicable
• 閃點（°C）: Not applicable